^
Association details:
| Biomarker: | BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Fusion in BRAF have also shown responses to MEK inhibitors and non specific RAF inhibitors (eg, sorafenib).
